All you need to know about managing hepatitis C virus infection in Australia

What’s new in the September 2018 Consensus Statement?

  • PBS listing of glecaprevir plus pibrentasvir
  • TGA approval of sofosbuvi plus velpatasvir plus voxilaprevir
  • Simplified recommendations for on-treatment monitoring
  • New recommendations for the management of non-responders to DAA therapy
  • New recommendations for the management of HCV in the setting of renal impairment
Read More

BROWSE TOPICS

Epidemiology and Models of Care

Screening and diagnosis

Pre-treatment assessment

Treatment for chronic hepatitis C

On-treatment monitoring

Post-treatment follow-up

Treating special populations

Decompensated liver disease After liver transplantation HIV coinfection HBV coinfection Renal impairment Acute HCV infection

DAA therapy & risk of HCC in people with cirrhosis

CONTRIBUTORS